Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines.


Journal

The Lancet. Oncology
ISSN: 1474-5488
Titre abrégé: Lancet Oncol
Pays: England
ID NLM: 100957246

Informations de publication

Date de publication:
09 2020
Historique:
received: 21 02 2020
revised: 13 05 2020
accepted: 19 05 2020
pubmed: 6 9 2020
medline: 24 9 2020
entrez: 5 9 2020
Statut: ppublish

Résumé

Population-based cancer registries (PBCRs) generate measures of cancer incidence and survival that are essential for cancer surveillance, research, and cancer control strategies. In 2014, the Toronto Paediatric Cancer Stage Guidelines were developed to standardise how PBCRs collect data on the stage at diagnosis for childhood cancer cases. These guidelines have been implemented in multiple jurisdictions worldwide to facilitate international comparative studies of incidence and outcome. Robust stratification by risk also requires data on key non-stage prognosticators (NSPs). Key experts and stakeholders used a modified Delphi approach to establish principles guiding paediatric cancer NSP data collection. With the use of these principles, recommendations were made on which NSPs should be collected for the major malignancies in children. The 2014 Toronto Stage Guidelines were also reviewed and updated where necessary. Wide adoption of the resultant Paediatric NSP Guidelines and updated Toronto Stage Guidelines will enhance the harmonisation and use of childhood cancer data provided by PBCRs.

Identifiants

pubmed: 32888473
pii: S1470-2045(20)30320-X
doi: 10.1016/S1470-2045(20)30320-X
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e444-e451

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Sumit Gupta (S)

Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada. Electronic address: sumit.gupta@sickkids.ca.

Joanne Aitken (J)

Cancer Council Queensland, Brisbane, QLD, Australia.

Ute Bartels (U)

Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.

Nickhill Bhakta (N)

Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.

Mihaela Bucurenci (M)

Romanian National Child Cancer Registry, Constanta, Romania.

James D Brierley (JD)

Radiation Medicine Program, Princess Margaret Hospital, Toronto, ON, Canada.

Beatriz De Camargo (B)

Research Centre, National Cancer Institute National Cancer Institute, Rio de Janeiro, Brazil.

Eric Chokunonga (E)

The Zimbabwe National Cancer Registry, Harare, Zimbabwe.

Jessica Clymer (J)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.

Dana Coza (D)

Romanian National Child Cancer Registry, Constanta, Romania.

Chris Fraser (C)

Department of Oncology, Children's Health Queensland Hospital, South Brisbane, QLD, Australia.

Soad Fuentes-Alabi (S)

Ayúdame a Vivir Medical Center, San Salvador, El Salvador.

Gemma Gatta (G)

Istituto Nazionale dei Tumori, Milan, Italy.

Thomas Gross (T)

National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

Zsuzsanna Jakab (Z)

Hungarian Childhood Cancer Registry, Semmelweis University, Budapest, Hungary.

Betsy Kohler (B)

North American Association of Central Cancer Registries, Springfield, IL, USA.

Tezer Kutluk (T)

Department of Paediatric Oncology, Hacettepe University Faculty of Medicine and Cancer Institute, Ankara, Turkey.

Florencia Moreno (F)

Argentina National Cancer Institute, Buenos Aires, Argentina.

Kayo Nakata (K)

Cancer Control Centre, Osaka International Cancer Institute, Osaka, Japan.

Sari Nur (S)

Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Jawa Barat, Indonesia.

D M Parkin (DM)

Nuffield Department of Population Health, University of Oxford, Oxford, UK; Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Lynne Penberthy (L)

National Cancer Institute, National Institute of Health, Bethesda, MD, USA.

Jason Pole (J)

Pediatric Group of Ontario, Toronto, ON, Canada.

Jenny N Poynter (JN)

Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

Kathy Pritchard-Jones (K)

University College London, London, UK.

Oscar Ramirez (O)

Centro Médico Imbanaco, Cali, Valle del Cauca, Colombia.

Lorna Renner (L)

University of Ghana School of Medicine, Accra, Ghana.

Eva Steliarova-Foucher (E)

Section of Cancer Surveillance, International Agency for Research on Cancer, Lyon, France.

Michael Sullivan (M)

Faculty of Medicine, University of Melbourne, Parkville, VIC, Australia.

Rajaraman Swaminathan (R)

Cancer Institute (WIA), Chennai, Tamil Nadu, India.

Liesbet Van Eycken (L)

Belgian Cancer Registry, Saint-Josse-ten-Noode, Belgium.

Tushar Vora (T)

Tata Memorial Centre, Mumbai, Maharashtra, India.

A L Frazier (AL)

Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH